Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and exhibits anti-proliferative properties. It promotes apoptosis by activating caspase-3 and elevating levels of cleaved polyADP-ribose polymerase, in addition to enhancing maturation and antigen presentation in dendritic cells. Moreover, STAT3-IN-18 has demonstrated in vivo safety. |
In vitro | STAT3-IN-18 at a concentration of 0.5 μM for 48 hours inhibits the phosphorylation of STAT3 and JAK2 in MDA-MB-231 cells, reduces the protein levels of Bcl-2 and COX-2, and increases the protein levels of Bak, Caspase-3, and Cleaved-PARP1 [1]. Additionally, STAT3-IN-18 at 0.5 μM for 36 hours induces cell cycle arrest at the S phase and promotes apoptosis in MDA-MB-231 cells after 48 hours of treatment. |
In vivo | STAT3-IN-18, administered bi-daily at an equivalent dose of 1.5 mg Pt for a total of 18 days, inhibited STAT3 phosphorylation and suppressed tumor growth in the 4T1 xenograft mouse model. The median lethal dose (LD50) of STAT3-IN-18 was determined to be 10.45 mg/kg [1]. |
Molecular Weight | 630.38 |
Formula | C18H24Cl2N2O6Pt |
Cas No. | 2668267-41-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.